国药现代化学原料药阿戈美拉汀上市申请获批

Core Viewpoint - The announcement by Guoyao Modern regarding the approval of the raw material drug Agomelatine by the National Medical Products Administration indicates a significant advancement in the company's product portfolio, particularly in the treatment of adult depression [1] Group 1: Company Developments - Guoyao Modern's wholly-owned subsidiary, Jiangsu Weichida Pharmaceutical Co., Ltd., has received the approval notice for the listing application of the raw material drug Agomelatine [1] - The registration standard number for the chemical raw material drug is YBY73032025 [1] Group 2: Product Information - Agomelatine acts primarily through the agonism of melatonin receptors MT1 and MT2, along with the antagonism of 5-HT2C, to restore disrupted biological rhythms in patients, thereby exerting an antidepressant effect [1] - The clinical application of Agomelatine is mainly focused on the treatment of adult depression [1]